Shuji Hinuma

This inventor holds 46 USPTO granted patents and 7 EPO patents, primarily in G Protein-Coupled Receptors. Top assignees: Takeda Chemical Industries, Inc., Takeda Pharmaceutical Company Limited, Human Genome Sciences, Inc.. Active years: 1986-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuji Hinuma. Retrieved from https://idiyas.com/inventor/shuji-hinuma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 46

% Patents Active = 56.5

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 4.3

ph-index = 8

Forward Citations = 218(Granted Patents)

Location History:

Suita, JP (1986 - 1998)
Ibaraki, JP (1997 - 2010)
Osaka, JP (1993 - 2011)
Tsukuba, JP (1998 - 2011)

Company Filing History:

24 out of 1,858

Takeda Chemical Industries, Inc.

patents

19 out of 1,226

Takeda Pharmaceutical Company Limited

patents

2 out of 676

Human Genome Sciences, Inc.

Takeda Chemical Ind., Ltd.

patents

where one patent can have more than one assignee

Years Active: 1986-2011

Loading Chart...

Areas of Expertise:

G Protein-Coupled Receptor

Ligands

Screening Method

Polypeptides

Therapeutic Agents

Receptor Function Regulator

Peptides

Antibodies

DNA

Condensed-Ring Thiophene Derivatives

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7972800 - Screening method for binding property or signal transduction alterations (2011-07-05),

2. 7960369 - Receptor function regulator (2011-06-14),

3. 7943137 - FPRL1 ligands and use thereof (2011-05-17),

4. 7927821 - Methods of screening for compounds which bind G protein-coupled receptors (2011-04-19),

5. 7833722 - Ligands for G protein-coupled receptor protein and use thereof (2010-11-16),

6. 7799533 - Polypeptides, their production and use (2010-09-21),

7. 7662574 - Use of a G protein-coupled receptor and its cognizant ligand in the identification of compounds that affect prolactin secretion (2010-02-16),

8. 7635751 - Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof (2009-12-22),

9. 7625887 - Receptor agonists (2009-12-01),

10. 7598351 - Antibody and use thereof (2009-10-06),

11. 7517661 - Methods of screening for ligands for FPRL2 (2009-04-14),

12. 7410776 - Polypeptides, their production and use (2008-08-12),

13. 7268212 - Ligand of G protein-coupled receptor protein and DNA thereof (2007-09-11),

14. 7217808 - RFRP-3 and DNA thereof (2007-05-15),

15. 7214495 - Screening method (2007-05-08),

Title: **Shuji Hinuma: A Pioneer in Pharmacological Innovations**

Introduction

Shuji Hinuma, based in Tsukuba, Japan, is a notable inventor with an impressive portfolio of 46 patents. His contributions to the fields of pharmacology and biochemistry have made significant impacts in the understanding and treatment of various medical conditions.

Latest Patents

Among his latest patents is a "Screening method for binding property or signal transduction alterations," which utilizes a G protein-coupled receptor protein with an amino acid sequence that is either identical or closely related to SEQ ID NO: 1. This innovative method incorporates an ionizable metal element, allowing for the efficient screening of agonists or antagonists for receptor proteins.

Another significant patent is the "Receptor function regulator," which revolves around the GPR40 receptor. This invention involves a compound featuring an aromatic ring and a cation-releasing group, marking its utility as an insulin secretagogue and a potential agent in the prevention and treatment of diabetes and related conditions.

Career Highlights

Shuji Hinuma has had a distinguished career with notable organizations such as Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His work at these leading pharmaceutical companies has been essential in advancing drug development strategies.

Collaborations

Throughout his career, Hinuma has collaborated with esteemed colleagues, including Ryo Fujii and Masaki Hosoya. These partnerships have fostered a productive environment for innovation and the advancement of pharmacological research.

Conclusion

Shuji Hinuma stands out as a prominent figure in the field of drug innovation, with his extensive patent portfolio reflecting his commitment to enhancing medical science. His inventions continue to pave the way for new therapeutic modalities, particularly in the realm of diabetes and receptor regulation.

Profile summary based on public USPTO records.